Abstract
High myopia is a major cause of uncorrectable visual impairment. It imposes major challenges and costs for refractive correction, and for the treatment of associated pathological complications. In the last 60 years, there has been a marked increase in the prevalence of high myopia in younger generations in developed countries in East and Southeast Asia, and there are signs of similar, but less pronounced increases in North America and Europe. In some parts of the world, 70-90% of children completing high schools are now myopic, and as many as 20% may be highly myopic. It is now clear that myopia results from excessive axial elongation of the eye, and this greater rate of axial elongation appears to be environmentally driven.
Experimental studies have examined the biochemical mechanisms involved in regulation of axial elongation; and, from these studies, some options have emerged for preventing the development of myopia or slowing myopia progression. Atropine eye drops have been quite extensively used in clinical practice in Asian countries. This long-lasting treatment could be beneficial, but has clear limitations and complications. Recent reports suggest that a low concentration of atropine, which has less severe side-effects, is also effective. But, a decision to use an invasive treatment such as atropine drops, even at low doses, requires careful consideration of the risk of myopia progression. A decision to use atropine in pre-myopic patients would require even more careful consideration of the risks. Here, we review the current literature relevant to the prevention of myopia progression with atropine drops.
Keywords: Myopia, progression, diluted atropine.
Current Pharmaceutical Design
Title:The Role of Atropine Eye Drops in Myopia Control
Volume: 21 Issue: 32
Author(s): Andrzej Grzybowski, Alejandro Armesto, Maria Szwajkowska, Guillermo Iribarren and Rafael Iribarren
Affiliation:
Keywords: Myopia, progression, diluted atropine.
Abstract: High myopia is a major cause of uncorrectable visual impairment. It imposes major challenges and costs for refractive correction, and for the treatment of associated pathological complications. In the last 60 years, there has been a marked increase in the prevalence of high myopia in younger generations in developed countries in East and Southeast Asia, and there are signs of similar, but less pronounced increases in North America and Europe. In some parts of the world, 70-90% of children completing high schools are now myopic, and as many as 20% may be highly myopic. It is now clear that myopia results from excessive axial elongation of the eye, and this greater rate of axial elongation appears to be environmentally driven.
Experimental studies have examined the biochemical mechanisms involved in regulation of axial elongation; and, from these studies, some options have emerged for preventing the development of myopia or slowing myopia progression. Atropine eye drops have been quite extensively used in clinical practice in Asian countries. This long-lasting treatment could be beneficial, but has clear limitations and complications. Recent reports suggest that a low concentration of atropine, which has less severe side-effects, is also effective. But, a decision to use an invasive treatment such as atropine drops, even at low doses, requires careful consideration of the risk of myopia progression. A decision to use atropine in pre-myopic patients would require even more careful consideration of the risks. Here, we review the current literature relevant to the prevention of myopia progression with atropine drops.
Export Options
About this article
Cite this article as:
Grzybowski Andrzej, Armesto Alejandro, Szwajkowska Maria, Iribarren Guillermo and Iribarren Rafael, The Role of Atropine Eye Drops in Myopia Control, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909095403
DOI https://dx.doi.org/10.2174/1381612821666150909095403 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PP2A and Alzheimer Disease
Current Alzheimer Research Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine Inhibition of Protein Misfolding and Aggregation by Small Rationally-Designed Peptides
Current Pharmaceutical Design Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology Cognitive Impairment in Depression
Current Psychiatry Reviews Cytochrome P450 in Neurological Disease
Current Drug Metabolism Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Novel Biosynthesis, Metabolism and Physiological Functions of L-Homoarginine
Current Protein & Peptide Science Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets Opinion Paper: A Cognitive-cultural Segregation and the Three Stages of Aging
Current Aging Science Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Impact of Introducing Catheter-based Renal Denervation into Japan for Hypertension Management: Estimation of Number of Target Patients and Clinical Relevance of Ambulatory Blood Pressure Reduction
Current Hypertension Reviews